Evidence map›Paper›PMID 20812725›Full record

ArticleJournal of medicinal chemistry2010

1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain.

Tristan E Rose, Christophe Morisseau, Jun-Yan Liu, Bora Inceoglu, Paul D Jones, James R Sanborn, Bruce D Hammock

Open access · greenAbstract readComparative Study
In one paragraph

Article in Journal of medicinal chemistry, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 131 papers.

0numbers the graph read from it
0cells of the map it votes in
131citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

131 citing papers in PubMed, 181 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Soluble Epoxide Hydrolase Inhibitors Improve Cornea Alkali Wound Healing.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. ACS medicinal chemistry letters · 2024
    Article
  19. Article
  20. Article

71 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Tristan E RoseDepartment of Entomology and University of California Davis Cancer Center, University of California, One Shields Avenue, Davis, California 95616, USA.
Christophe Morisseau
Jun-Yan Liu
Bora Inceoglu
Paul D Jones
James R Sanborn
Bruce D Hammock
University of California, Davis · US

Funding

Workshop on Environmental Technology Transfer and EntrepreneurshipP42ES004699 · NIEHS · UNIVERSITY OF CALIFORNIA DAVIS · PI VASYLIEVA, NATALIA · 1987 to 2021
$50.1M
HYDROLYTIC ENZYMES IN THE METABOLISM OF TOXINSR01ES002710 · NIEHS · UNIVERSITY OF CALIFORNIA DAVIS · PI HAMMOCK, BRUCE D · 1985 to 2018
$4.0M
OXYGENASE METABOLITES AND RENAL VASCULAR ACTIVITYR01HL059699 · NHLBI · TULANE UNIVERSITY OF LOUISIANA · PI IMIG, JOHN D · 1999 to 2011
$3.0M
NHLBI NIH HHS R01 HL059699NIEHS NIH HHS P42 ES004699NIEHS NIH HHS R01 ES002710
6 · The paper itself

Abstract

1,3-Disubstituted ureas possessing a piperidyl moiety have been synthesized to investigate their structure-activity relationships as inhibitors of the human and murine soluble epoxide hydrolase (sEH). Oral administration of 13 1-aryl-3-(1-acylpiperidin-4-yl)urea inhibitors in mice revealed substantial improvements in pharmacokinetic parameters over previously reported 1-adamantylurea based inhibitors. For example, 1-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea (52) showed a 7-fold increase in potency, a 65-fold increase in C(max), and a 3300-fold increase in AUC over its adamantane analogue 1-(1-adamantyl)-3-(1-propionylpiperidin-4-yl)urea (2). This novel sEH inhibitor showed a 1000-fold increase in potency when compared to morphine by reducing hyperalgesia as measured by mechanical withdrawal threshold using the in vivo carrageenan induced inflammatory pain model.

Indexed as

AdamantaneAnalgesics, OpioidAnimalsAnti-Inflammatory Agents, Non-SteroidalCarrageenanEpoxide HydrolasesHumansMaleMiceMorphinePainPiperidinesRatsRats, Sprague-DawleySolubilityStructure-Activity RelationshipAdamantaneAnalgesics, OpioidAnti-Inflammatory Agents, Non-SteroidalCarrageenanEpoxide HydrolasesMorphinePiperidinesUrea

Identifiers

PMID20812725
PMCPMC3285450
OpenAlexW2117356638

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.